



28 March 2023

ASX ANNOUNCEMENT

ImpediMed NCCN Investor Update Conference Call Notification

ImpediMed Limited (**ImpediMed** or the **Company**) (ASX:IPD) advises it will hold an investor conference call on Wednesday 29th March to update investors on the National Comprehensive Cancer Network® (NCCN®) Guidelines update which now recommends regular screening for lymphoedema including with bioimpedance spectroscopy (BIS), as noted in the 27 March 2023 ASX Announcement.

Investors are invited to join a live webinar and Q&A hosted by Managing Director and CEO, Rick Valencia at 9.30am (AEDT) on Wednesday 29th March 2023.

To pre-register, please follow this link:

<https://s1.c-conf.com/diamondpass/10029871-r4917o.html>

Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.

Approved for release by the Managing Director and CEO, Mr Rick Valencia.

Contact Details

Investor relations Contact:

Hannah Howlett

WE Communications

T: +61 (0) 4 5064 8064

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

About the PREVENT Trial

The PREVENT trial is a pivotal study, the largest randomised controlled trial to assess lymphoedema prevention. This international, multi-institutional randomised controlled trial provided level I evidence demonstrating that intervention in patients with early detection of cancer-related lymphoedema using ImpediMed's L-Dex® technology resulted in a lower rate of progression to chronic disease than patients with early detection from volume measurements using a tape measure. The statistically significant results demonstrated that bioimpedance spectroscopy (BIS) screening should be a standard approach for prospective breast cancer-related lymphoedema (BCRL) surveillance. The trial followed over 1,200 patients for three years across 13 medical centers across the US and Australia. Patients enrolled in the study included breast cancer survivors whose treatment puts them at risk for developing secondary, chronic lymphoedema in one of their arms. These patients were randomised to follow up monitoring for lymphoedema development using either L-Dex or tape measure-based volume measurements.

About SOZO Digital Health Platform

SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.